Preclinical studies have shown that the activation and elevated expression of focal adhesion kinase (FAK) is associated with tumor progression, invasion, and drug resistance in solid tumors, prompting the development of FAK inhibitors. The gene discussed is PTK2; the disease is neoplasm.